Significance StatementIdentifying and stratifying patients that will respond to cell‐based therapies will be crucial to the success of these innovative therapeutic modalities. To our knowledge, this is the first report identifying circulating potential microRNA biomarkers associated with patient response to a cell‐based therapy.

Introduction {#sct312017-sec-0002}
============

Rheumatoid arthritis (RA) is a common chronic, inflammatory, autoimmune disease which leads to progressive disability and morbidity with resulting significant socioeconomic costs [1](#sct312017-bib-0001){ref-type="ref"}. The cause of RA is unknown and it is a particularly complex and heterogeneous disease. Due to this, although advances in understanding the pathogenesis have resulted in the development of new therapeutic approaches, current conventional and biologic disease‐modifying therapies still fail and/or produce only partial responses in many patients [1](#sct312017-bib-0001){ref-type="ref"}, [2](#sct312017-bib-0002){ref-type="ref"}. Patient stratification in RA is limited or nonexistent, particularly for biologics [2](#sct312017-bib-0002){ref-type="ref"}. Therefore, identifying pretreatments predictors of response is likely to be highly valuable in RA [2](#sct312017-bib-0002){ref-type="ref"}. Certainly, the ability to identify and stratify patients that will respond to specific therapies has been transformational in a number of other disease areas, particularly oncology [3](#sct312017-bib-0003){ref-type="ref"}.

Given the clear unmet medical need in RA, cell‐based therapies such as adult mesenchymal stem cells offer much potential utility and early indications suggest that they could be promising new treatments in RA [4](#sct312017-bib-0004){ref-type="ref"}, [5](#sct312017-bib-0005){ref-type="ref"}. Indeed, recent clinical results from intravenous administration of expanded allogenic adipose‐derived mesenchymal stem cells (eASCs) indicated a trend for clinical efficacy in highly refractory RA patients [6](#sct312017-bib-0006){ref-type="ref"}. As with current conventional and biologic disease‐modifying therapies for RA, identifying and stratifying patients that will respond to cell‐based therapies will be crucial to the success of these innovative therapeutic modalities in RA.

MicroRNAs (miRNAs) are single‐stranded noncoding RNA molecules around 21 to 23 nucleotides in length. They regulate gene expression in cells by hybridization to mRNA transcripts, resulting in translational blockade or transcript degradation [7](#sct312017-bib-0007){ref-type="ref"} and have important roles in multiple biological processes and pathological processes [7](#sct312017-bib-0007){ref-type="ref"}, [8](#sct312017-bib-0008){ref-type="ref"}. MiRNAs also have many attributes that make them ideal as biomarkers. MiRNAs can be readily sampled and assayed in a variety of biofluids [9](#sct312017-bib-0009){ref-type="ref"} and unlike messenger mRNA and proteins, they are highly resistant to enzymatic degradation and are very stable in biofluids, even after long‐term storage and multiple freeze‐thaw cycles [10](#sct312017-bib-0010){ref-type="ref"}, [11](#sct312017-bib-0011){ref-type="ref"}. There is an increasing focus on assaying circulating miRNAs in biofluids as biomarkers for a wide variety of applications. Recently, several circulating serum miRNAs have been identified a potential biomarker predicting response to conventional and biologic disease‐modifying therapies [12](#sct312017-bib-0012){ref-type="ref"}, [13](#sct312017-bib-0013){ref-type="ref"}. To our knowledge, however, there have been no reports identifying stratification miRNA biomarkers predicting patient response to a cell‐based therapy.

The aim of this study, using clinical trial samples and miRNA microarray and quantitative reverse‐transcriptase polymerase chain reaction (QRT‐PCR) analyses, was to identify candidate miRNA stratification biomarkers associated with eASC therapy response in RA.

Materials and Methods {#sct312017-sec-0003}
=====================

eASC treatment responder and nonresponder patients from a clinical trial of intravenous administration of eASCs in refractory RA patients were selected (Supporting Information data) for circulating miRNA biomarker analysis [6](#sct312017-bib-0006){ref-type="ref"}. RNA was extracted from 0.5 ml plasma taken 2 weeks prior to treatment (Exiqon, Denmark, <http://www.exiqon.com>) and analyzed on miRNA microarrays (Agilent Technologies, U.K., <http://www.agilent.com>). Data preprocessing and normalization was carried with the "AgiMicroRNA" [14](#sct312017-bib-0014){ref-type="ref"} package in Bioconductor [15](#sct312017-bib-0015){ref-type="ref"}. miRNAs differentially expressed between the responder and nonresponder groups were identified by fold change analysis and the top 10 most highly differentially expressed were selected. Candidate miRNAs for normalizing QRT‐PCR data were identified using the Two One‐Sided Tests approach (pFDR \< 0.1, fold‐change \< 2.0) [16](#sct312017-bib-0016){ref-type="ref"}. Expression analysis of the differentially expressed miRNAs was carried out by QRT‐PCR (Exiqon) using a Roche LightCycler 480 (Roche Diagnostics Ltd, UK, <http://www.roche.co.uk>). Identification of miRNAs for data normalization and QRT‐PCR comparative C*q* data analysis was carried out using Biogazelle qbase+ v 2.5 (Biogazelle, Belgium, <https://www.biogazelle.com>). Mean fold changes were determined between normalized relative expression values for responder and nonresponder groups and tested for statistical significance using Student\'s *t* test (*p* \<.05). Receiver operating characteristic (ROC) analysis was performed using the "ROCR" package [17](#sct312017-bib-0017){ref-type="ref"} in R.

Results and Discussion {#sct312017-sec-0004}
======================

Microarray Analysis {#sct312017-sec-0005}
-------------------

To identify candidate miRNA stratification biomarkers for response to eASC treatment in highly refractory RA patients, RNA from pretreatment plasma samples from responder and nonresponder patients (Supporting Information data) were analyzed on miRNA microarrays. Using fold change analysis, we selected the 10 most highly differentially expressed between responders and nonresponders as potential miRNA biomarkers for response to eASC treatment (Figs. [1](#sct312017-fig-0001){ref-type="fig"} and [2](#sct312017-fig-0002){ref-type="fig"}). It should be noted that red blood cells contain high levels of miRNAs, and identification of circulating miRNA biomarkers in plasma and serum can be severely confounded by differing levels of hemolysis occurring in these samples during collection and processing [18](#sct312017-bib-0018){ref-type="ref"}. However, the potential miRNA biomarkers identified here were not amongst the miRNAs specifically reported to be elevated by hemolysis [19](#sct312017-bib-0019){ref-type="ref"}.

![MicroRNA (miRNA) microarray expression data showing circulating miRNAs identified as being upregulated in plasma samples in the responder group as compared to the nonresponder group. The expression data is given as normalized signal intensities on a log 2 scale. Data is shown for the responder samples (*n* = 10) and nonresponder samples (*n* = 8) which generated microarray data from the 10 responder and 10 nonresponder samples analyzed (see Supporting Information data for details). Short solid lines on graphs indicates mean expression in each group. Dotted line on graphs indicates the lower limit of detection on the miRNA microarrays.](SCT3-6-1202-g001){#sct312017-fig-0001}

![MicroRNA (miRNA) microarray expression data showing circulating miRNAs identified as being downregulated in plasma samples in the responder group as compared to the nonresponder group. The expression data is given as normalized signal intensities on a log 2 scale. Data is shown for the responder samples (*n* = 10) and nonresponder samples (*n* = 8) which generated microarray data from the 10 responder and 10 nonresponder samples analyzed (see Supporting Information data for details). Short solid lines on graphs indicates mean expression in each group. Dotted line on graphs indicates the lower limit of detection on the miRNA microarrays.](SCT3-6-1202-g002){#sct312017-fig-0002}

QRT‐PCR Analysis {#sct312017-sec-0006}
----------------

The expression of these candidate miRNA biomarkers was then further investigated by QRT‐PCR. For normalization, we identified a set of 10 candidate normalizer miRNAs from the miRNA microarray data. There are no established universal normalizer miRNAs for plasma and case‐specific normalizers need to be identified and tested [20](#sct312017-bib-0020){ref-type="ref"}. This was therefore an important part of the analysis to allow normalization of QRT‐PCR data and accurate assessment of miRNA relative expression between the two responder groups. miR‐93‐5p and miR‐324‐3p were selected as normalizers and used to normalize the QRT‐PCR data. Of the selected miRNA biomarkers, miR‐26b‐5p and miR‐495‐3p were confirmed as being significantly upregulated (*p* = .01, .02; fold change = 1.3, 2.4, respectively), in the responder group, and miR‐487b‐3p was very close to being significantly upregulated (*p* = .05; fold change = 2.2; Fig. [3](#sct312017-fig-0003){ref-type="fig"}). The diagnostic potential of these miRNAs was further investigated by generating ROC curves [21](#sct312017-bib-0021){ref-type="ref"} based on the QRT‐PCR data (Supporting Information data) and calculating the area under the curve (AUC). Though this analysis is likely to generate optimistic results in the absence of an independent sample set, the high AUC values of 0.9 (miR‐26b‐5p) and 0.8 (miR‐487b‐3p and miR‐495‐3p) support the ability of these miRNAs to allow discrimination between responders and nonresponders.

![Quantitative reverse‐transcriptase PCR (QRT‐PCR) expression data showing expression levels of candidate circulating miRNA stratification biomarkers in plasma samples in the responder group and the nonresponder group. The expression data is given as relative normalized expression on a linear scale. Data is shown for the responder samples (*n* = 7) and nonresponder samples (*n* = 7) which generated QRT‐PCR data from the 11 responder and 11 nonresponder samples analyzed (see Supporting Information data for details). Short solid lines on graphs indicates mean expression in each group. \*, miR‐26b‐5p, *p* = .01; miR‐495‐3p, *p* = .02. \*\*, miR‐487b‐3p, *p* = .05.](SCT3-6-1202-g003){#sct312017-fig-0003}

All three of these miRNAs have also reported to be present in plasma/serum [9](#sct312017-bib-0009){ref-type="ref"}, [20](#sct312017-bib-0020){ref-type="ref"}, [22](#sct312017-bib-0022){ref-type="ref"}, although there appears to be no reports identifying these miRNAs being present in plasma/serum from RA patients. miR‐487b‐3p has been reported to be upregulated in RA synovial monocytes compared with normal peripheral blood monocytes [23](#sct312017-bib-0023){ref-type="ref"}. It is currently unclear what role(s) they may play in RA and the underlying mechanisms by which they are associated with response to cell‐based therapy. Nevertheless, these three miRNAs could represent potential candidate biomarkers associated with RA patient response to eASC‐based therapy.

Conclusion {#sct312017-sec-0007}
==========

In a highly refractory RA patient population treated with eASCs we identified three circulating miRNAs that were upregulated in the responder group compared with the nonresponder group and represent candidate biomarkers for success of eASC therapy treatment. The sample size in this study was relatively small and these candidates require validation in multiple, larger independent sample sets. However, this is an important first step, and to our knowledge, the first report identifying potential circulating miRNA biomarkers associated with patient response to a cell‐based therapy.
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